Three Prospective Case Studies Examining Mifepristone’s Efficacy in Patients with Treatment-Resistant PTSD
Despite the availability of various treatment approaches for patients with posttraumatic stress disorder (PTSD), some patients do not respond to these therapies, and novel treatment approaches are needed. This study investigated the efficacy of mifepristone, a glucocorticoid receptor antagonist, in...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | Case Reports in Psychiatry |
| Online Access: | http://dx.doi.org/10.1155/2024/4768647 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553136691085312 |
|---|---|
| author | Agnes van Minnen Lizelotte Vos Pierre M. Bet Ad de Jongh Felix Linsen Hein J. F. van Marle Onno C. Meijer Willem M. Otte Marije Russcher Christiaan H. Vinkers |
| author_facet | Agnes van Minnen Lizelotte Vos Pierre M. Bet Ad de Jongh Felix Linsen Hein J. F. van Marle Onno C. Meijer Willem M. Otte Marije Russcher Christiaan H. Vinkers |
| author_sort | Agnes van Minnen |
| collection | DOAJ |
| description | Despite the availability of various treatment approaches for patients with posttraumatic stress disorder (PTSD), some patients do not respond to these therapies, and novel treatment approaches are needed. This study investigated the efficacy of mifepristone, a glucocorticoid receptor antagonist, in treatment-resistant PTSD patients. Three patients with PTSD who were resistant to standard psychological and pharmacological treatments were prescribed mifepristone (600–1,200 mg/day) for 1 week. A baseline-controlled single-case design was used, involving a 2-week baseline phase (no intervention), a 1-week intervention phase (mifepristone), and a 2-week postintervention phase. The primary outcome measure, self-reported PTSD symptom severity (PCL-5), was assessed daily, with participants providing their own control condition. Two of the three patients experienced a significant reduction in PTSD symptom severity after the intervention phase and no longer met the diagnostic criteria for PTSD. These positive results were maintained during long-term follow-up. These findings support the potential effectiveness of mifepristone in the treatment of patients with treatment-resistant PTSD. However, our findings must be interpreted with caution, and further studies with larger sample sizes and more rigorous designs are necessary to confirm the promising results. |
| format | Article |
| id | doaj-art-8c8392000c1d4da7902ea8fa4857941e |
| institution | Kabale University |
| issn | 2090-6838 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Psychiatry |
| spelling | doaj-art-8c8392000c1d4da7902ea8fa4857941e2025-02-03T05:55:21ZengWileyCase Reports in Psychiatry2090-68382024-01-01202410.1155/2024/4768647Three Prospective Case Studies Examining Mifepristone’s Efficacy in Patients with Treatment-Resistant PTSDAgnes van Minnen0Lizelotte Vos1Pierre M. Bet2Ad de Jongh3Felix Linsen4Hein J. F. van Marle5Onno C. Meijer6Willem M. Otte7Marije Russcher8Christiaan H. Vinkers9Psychotrauma Expertise Centre (PSYTREC) BilthovenPsychotrauma Expertise Centre (PSYTREC) BilthovenDepartment of Clinical Pharmacology and PharmacyPsychotrauma Expertise Centre (PSYTREC) BilthovenDepartment of PsychiatryARQ National Psychotrauma CenterDepartment of MedicineDepartment of Child NeurologyDepartment of Hospital PharmacyGGZ inGeest Mental Health CareDespite the availability of various treatment approaches for patients with posttraumatic stress disorder (PTSD), some patients do not respond to these therapies, and novel treatment approaches are needed. This study investigated the efficacy of mifepristone, a glucocorticoid receptor antagonist, in treatment-resistant PTSD patients. Three patients with PTSD who were resistant to standard psychological and pharmacological treatments were prescribed mifepristone (600–1,200 mg/day) for 1 week. A baseline-controlled single-case design was used, involving a 2-week baseline phase (no intervention), a 1-week intervention phase (mifepristone), and a 2-week postintervention phase. The primary outcome measure, self-reported PTSD symptom severity (PCL-5), was assessed daily, with participants providing their own control condition. Two of the three patients experienced a significant reduction in PTSD symptom severity after the intervention phase and no longer met the diagnostic criteria for PTSD. These positive results were maintained during long-term follow-up. These findings support the potential effectiveness of mifepristone in the treatment of patients with treatment-resistant PTSD. However, our findings must be interpreted with caution, and further studies with larger sample sizes and more rigorous designs are necessary to confirm the promising results.http://dx.doi.org/10.1155/2024/4768647 |
| spellingShingle | Agnes van Minnen Lizelotte Vos Pierre M. Bet Ad de Jongh Felix Linsen Hein J. F. van Marle Onno C. Meijer Willem M. Otte Marije Russcher Christiaan H. Vinkers Three Prospective Case Studies Examining Mifepristone’s Efficacy in Patients with Treatment-Resistant PTSD Case Reports in Psychiatry |
| title | Three Prospective Case Studies Examining Mifepristone’s Efficacy in Patients with Treatment-Resistant PTSD |
| title_full | Three Prospective Case Studies Examining Mifepristone’s Efficacy in Patients with Treatment-Resistant PTSD |
| title_fullStr | Three Prospective Case Studies Examining Mifepristone’s Efficacy in Patients with Treatment-Resistant PTSD |
| title_full_unstemmed | Three Prospective Case Studies Examining Mifepristone’s Efficacy in Patients with Treatment-Resistant PTSD |
| title_short | Three Prospective Case Studies Examining Mifepristone’s Efficacy in Patients with Treatment-Resistant PTSD |
| title_sort | three prospective case studies examining mifepristone s efficacy in patients with treatment resistant ptsd |
| url | http://dx.doi.org/10.1155/2024/4768647 |
| work_keys_str_mv | AT agnesvanminnen threeprospectivecasestudiesexaminingmifepristonesefficacyinpatientswithtreatmentresistantptsd AT lizelottevos threeprospectivecasestudiesexaminingmifepristonesefficacyinpatientswithtreatmentresistantptsd AT pierrembet threeprospectivecasestudiesexaminingmifepristonesefficacyinpatientswithtreatmentresistantptsd AT addejongh threeprospectivecasestudiesexaminingmifepristonesefficacyinpatientswithtreatmentresistantptsd AT felixlinsen threeprospectivecasestudiesexaminingmifepristonesefficacyinpatientswithtreatmentresistantptsd AT heinjfvanmarle threeprospectivecasestudiesexaminingmifepristonesefficacyinpatientswithtreatmentresistantptsd AT onnocmeijer threeprospectivecasestudiesexaminingmifepristonesefficacyinpatientswithtreatmentresistantptsd AT willemmotte threeprospectivecasestudiesexaminingmifepristonesefficacyinpatientswithtreatmentresistantptsd AT marijerusscher threeprospectivecasestudiesexaminingmifepristonesefficacyinpatientswithtreatmentresistantptsd AT christiaanhvinkers threeprospectivecasestudiesexaminingmifepristonesefficacyinpatientswithtreatmentresistantptsd |